ABSTRACT
BACKGROUND: Surgical extraction of third molars is associated with postoperative pain and swelling at the extraction site. Pain is commonly managed using non-steroidal anti-inflammatory drugs (NSAIDs). Postoperative pain is usually moderate to severe in the first 12 h postoperatively and lasts for 3–5 days. However, with NSAIDs, these symptoms usually subside within 24 h. Diclofenac sodium and etodolac are NSAIDs, more selectively cyclooxygenase-2 inhibitors, with good analgesic efficacies.METHODS: We compared the safety and analgesic efficacy of diclofenac sodium with etodolac peroral after surgical extraction of third molars in a double-blind, double-dummy, parallel-group study. The subjective pain improvement and pain relief after 2, 6, 24, 48, and 72 h using the visual analogue scale were measured as the study outcome.RESULTS: Etodolac was equivalent to diclofenac sodium in pain alleviation at all postoperative time periods. No significant differences were found between diclofenac sodium and etodolac groups (P > 0.05). Both study medications were well tolerated and safe with mild adverse effects in only a few participants.CONCLUSION: Diclofenac sodium and etodolac are comparable in terms of analgesic efficacy and safety after surgical removal of third molars.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal , Cyclooxygenase 2 Inhibitors , Diclofenac , Etodolac , Molar, Third , Pain, Postoperative , Tooth Extraction , Visual Analog ScaleABSTRACT
Mucoadhesive microspheres are drug delivery system intended for targeting a drug to particular region. Etodolac is a Non-steroidal anti-inflammatory drug. The objective of the present work was to develop sustain release of Etodolac loaded mucoadhesive microspheres due to relatively short residence time in the GIT tract before elimination. Mucoadhesive microspheres were prepared by non-aqueous solvent evaporation method using Carbopol 974P, HPMC K100M and HPMC K4M as the polymers. Central composite design was selected for the development of the formulation. Evaluation parameters like particle size, entrapment efficiency, shape and surface morphology, degree of swelling, drug content, in-vitro drug release study and in-vitro drug release study was done. Based on the results obtained from the preliminary formulations three optimized formulations were designed. The percentage mucoadhesion and swelling index of the optimized formulation was found in the range of 66-70 % and 82.50-83.84 % respectively. Optimized formulation releases 90.94% to 92.11% of drug at the end of 10 hours and follows zero order release kinetics.
ABSTRACT
ABSTRACT Etodolac is a non-steroidal anti-inflammatory drug (NSAID) and approved by USFDA as a COX2 inhibitor. Although etodolac therapy provides clinical benefits, it is associated with upper gastrointestinal (GI) tract complications also. Etodolac loaded gum Katira microsphere (ELGKM) was prepared by W1/O/W2 emulsion solvent evaporation technique. The gastric irritation properties of orally administered pure etodolac, ELGKM and blank microspheres (without etodolac) were evaluated in experimental rats treated for 6 days. The stomach examination and biochemical investigation of stomach tissue of treated rats indicated that ELGKM formulation remarkably reduced ulcerogenecity as compared to pure etodolac. The anti-inflammatory activities of pure etodolac and ELGKMs were ascertained by the implantation of cotton pellets in rats for 6 days. Based on the results, ELGKMs showed significant anti-inflammatory activities (P<0.01) as compared to control group. The cotton pellets test suggested that ELGKM formulation retained more anti-inflammatory properties among the groups. The hematological changes, biochemical analysis and histopathological studies of subacute toxicity in rats revealed that ELGKM were the effective sustained release formulation in the treatment of chronic pain and inflammation. In conclusion, the physicochemical characterization, pharmacological and toxicological studies suggest that ELGKMs may represent as a potential candidate for sustained drug delivery (10-12 hours) in chronic joint pain related diseases with remarkably diminished gastrointestinal side effects.
Subject(s)
Animals , Male , Rabbits , Rats , Tragacanth/therapeutic use , Evaporation/methods , Etodolac/analysis , Etodolac/therapeutic use , Microspheres , Upper Gastrointestinal Tract/pathologyABSTRACT
OBJECTIVE:To establish HPLC method in the determination of the related substances in etodolac sustained released tablets.METHODS:The determination was performed with C 18 as the chromatographic column.The mobile phases consisted of methanol-acetonitrile-0.055mol/L ammonium acetate solution(60∶40∶900)and methnol-acetonitrile-0.5mol/L ammonium acetate solution(540∶360∶100),which were subjected to gradient elutions.Its flow rate of was1.0ml/min,the column temperature was35℃,the detection wavelength was220nm and the sample size was10?l.RESULTS:The main peaks of etodolac and the other peaks of the related foreign substances could be well isolated in all the specificity tests.The determination of the related substances of the3batches of samples can satisfy the determination requirements for the related substances in etodolac sustained released tablets.CONCLUSION:This method can be applied to determine the related sub?stances in etodolac sustained released tablets.
ABSTRACT
Nonpigmenting fixed drug eruption is a form of fixed drug eruption which heals without pigmentation. To leave no traces makes the diagnosis difficult. A 37-year-old man pressented the erythematous patches on both wrists and the left thigh. Several hours before the eruption, he had taken oral drugs for the treatment of osteomyelitis. He had had the same eruptions which were diagnosed as an allergic contact dermatitis, 8 months ago. The patch tests with medicated drugs were negative, but oral provocation with etodolac brought the same eruptions.